Safety of two-dose COVID-19 vaccination (BNT162b2 and CoronaVac) in adults with cancer: a territory-wide cohort study
Abstract Background The World Health Organization has defined a list of adverse events of special interest (AESI) for safety surveillance of vaccines. AESI have not been adequately assessed following COVID-19 vaccination in patients with cancer contributing to vaccine hesitancy in this population. W...
Main Authors: | Wei Kang, Jessica J. P. Shami, Vincent K. C. Yan, Xuxiao Ye, Joseph E. Blais, Xue Li, Victor H. F. Lee, Celine S. L. Chui, Francisco T. T. Lai, Eric Y. F. Wan, Carlos K. H. Wong, Ian C. K. Wong, Esther W. Chan |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-05-01
|
Series: | Journal of Hematology & Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13045-022-01265-9 |
Similar Items
-
Comparative effectiveness and safety of BNT162b2 and CoronaVac in Hong Kong: A target trial emulation
by: Eric Yuk Fai Wan, et al.
Published: (2024-09-01) -
Immunogenicity of Mix-and-Match CoronaVac/BNT162b2 Regimen versus Homologous CoronaVac/CoronaVac Vaccination: A Single-Blinded, Randomized, Parallel Group Superiority Trial
by: Samar Samoud, et al.
Published: (2023-08-01) -
BNT162b2 or CoronaVac Vaccinations Are Associated With a Lower Risk of Myocardial Infarction and Stroke After SARS‐CoV‐2 Infection Among Patients With Cardiovascular Disease
by: Xuxiao Ye, et al.
Published: (2023-05-01) -
Safety and immunogenicity of 3 doses of BNT162b2 and CoronaVac in children and adults with inborn errors of immunity
by: Daniel Leung, et al.
Published: (2022-09-01) -
Medium-term immunogenicity of three doses of BNT162b2 and CoronaVac in Hong Kong neuromuscular disease patients
by: Michael Kwan Leung Yu, et al.
Published: (2024-12-01)